$182 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 11 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS INC | $49,491,000 | +20.8% | 4,919,625 | 0.0% | 27.14% | +27.8% | |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $39,564,000 | +115.4% | 2,144,387 | +12.2% | 21.69% | +127.9% |
| SLXP | SALIX PHARMACEUTICALS INC | $34,482,000 | -26.4% | 300,000 | 0.0% | 18.91% | -22.2% | |
| New | OPKO HEALTH INCdebt 3.0% 2/1/33 | $20,573,000 | – | 14,000,000 | +100.0% | 11.28% | – | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $16,480,000 | +25.3% | 182,300 | 0.0% | 9.04% | +32.6% | |
| MERRIMACK PHARMACEUTICALS INCnote 4.5% 7/15/20 | $10,225,000 | +20.4% | 5,500,000 | 0.0% | 5.61% | +27.4% | ||
| HZNP | Buy | HORIZON PHARMA PLC | $6,316,000 | +71.4% | 490,000 | +63.3% | 3.46% | +81.4% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $4,416,000 | -12.6% | 238,432 | -17.3% | 2.42% | -7.5% |
| OGXI | New | ONCOGENEX PHARMACEUTICALS INC | $836,000 | – | 365,000 | +100.0% | 0.46% | – |
| AMBI | Exit | AMBIT BIOSCIENCES CORP | $0 | – | -46 | -100.0% | 0.00% | – |
| DNDNQ | Exit | DENDREON CORP | $0 | – | -55,548 | -100.0% | -0.04% | – |
| RXII | Exit | RXI PHARMACEUTICALS CORP | $0 | – | -50,219 | -100.0% | -0.05% | – |
| Exit | OPKO HEALTH INCnote 3.0% 2/1/33 | $0 | – | -14,000,000 | -100.0% | -9.72% | – | |
| Exit | PDL BIOPHARMA INCnote 2.875% 2/15/15 | $0 | – | -25,974,000 | -100.0% | -19.41% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-01-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.